Natera delivered 39.8% year-over-year revenue growth in Q4 2025 driven by higher product volumes and pricing improvements, expanded gross margin to 66.9%, and narrowed its operating loss compared to the prior year period.

Natera delivered excellent results in the third quarter of 2025, with total revenues increasing by 34.7% year-over-year to $592.2 million, primarily driven by a significant increase in product revenues and test volumes. Despite increased operating expenses, the company maintained a strong gross margin and ended the quarter with over $1 billion in cash and equivalents.

Natera delivered outstanding results in the second quarter of 2025, with total revenues increasing by 32.2% year-over-year to $546.6 million. This growth was primarily fueled by a 32.3% increase in product revenues and higher test volumes. Despite increased operating expenses, the company improved its gross margin and ended the quarter with over $1 billion in cash and equivalents.

Natera reported strong first quarter 2025 results with significant growth in total revenue and product revenue, driven by increased test volume and improved average selling prices. The company also saw an increase in gross profit and managed its net loss.

Natera's Q4 2024 revenue increased by 53% year-over-year to $476.1 million, primarily due to higher product revenue. The company processed 792,800 tests in the quarter, up 26.5% from Q4 2023. Gross margin improved to 62.9%, reflecting cost efficiencies. Net loss narrowed to $53.8 million from $78.0 million in the previous year.

Natera reported a strong third quarter with a 63.9% increase in total revenue to $439.8 million, driven by a 64.4% increase in product revenue. The company also saw improvements in gross margin and processed more tests compared to the same period last year.

Natera reported a strong second quarter with total revenues of $413.4 million, a 58.1% increase compared to the second quarter of 2023. The company processed approximately 760,300 tests and reported a net loss of $37.5 million, or ($0.30) per diluted share.

Natera reported a strong start to the year with significant growth in volume, revenue, and margin, achieving cash flow breakeven ahead of schedule. Total revenues increased by 52.1% to $367.7 million, driven by a 53.4% increase in product revenues. The company processed approximately 735,800 tests and reported a net loss of $67.6 million, or ($0.56) per diluted share.

Natera reported a strong fourth quarter in 2023, with total revenues increasing by 43.2% compared to the same period in 2022, driven by a significant increase in product revenues and test volumes. The company also saw improvements in gross margin and a reduction in net loss per share.

Natera reported a 27.4% increase in total revenues, reaching $268.3 million, driven by a 32.7% increase in product revenues. The company processed approximately 626,000 tests, reflecting a 21.0% increase. They have revised their 2023 annual revenue guidance to $1.035 billion to $1.05 billion.

Natera reported a strong second quarter with a 31.9% increase in total revenues, driven by a 32.7% increase in product revenues. The company processed approximately 617,200 tests and reported a net loss of $110.8 million, an improvement compared to the previous year. Natera is raising its full year revenue guidance.

Natera reported a 24.5% increase in total revenue to $241.8 million, driven by a 25.2% increase in product revenue due to higher test volumes. The company processed approximately 626,200 tests, with a net loss of $136.9 million, or ($1.23) per diluted share.

Natera reported a 25.6% increase in total revenues for Q4 2022, driven by a 28.2% increase in product revenues. The company processed approximately 559,700 tests and recognized revenue on approximately 519,200 tests.

Natera reported a 33.2% increase in total revenues, reaching $210.6 million in Q3 2022 compared to $158.1 million in Q3 2021. The growth was driven by a 29.8% increase in product revenues, totaling $199.8 million, and a 27.1% increase in test volumes, with approximately 517,500 tests processed.

Natera reported a 39.6% increase in total revenues, reaching $198.2 million in Q2 2022 compared to $142.0 million in Q2 2021. The company processed approximately 499,900 tests, including 484,000 accessioned in its laboratory. They are expecting to reach a cash flow breakeven quarter by mid-2024.

Natera reported a 27.5% increase in total revenues to $194.1 million for the first quarter of 2022, driven by a 57.8% increase in product revenues. The company processed 489,300 tests and reported a net loss of $138.6 million, or ($1.45) per diluted share. They are raising their 2022 revenue forecast by $20 million.

Natera's Q4 2021 total revenues increased by 53.9% compared to Q4 2020, driven by product revenue growth. The company processed 438,800 tests in the fourth quarter of 2021, including 424,200 tests accessioned in its laboratory.

Natera reported a 61.1% increase in total revenue, reaching $158.1 million, driven by a 61.5% increase in product revenues and a rise in test volumes. The company processed approximately 407,300 tests, with gross profit increasing to $76.7 million. However, the net loss was $151.3 million, or ($1.63) per diluted share, compared to a net loss of $58.3 million in the same period last year.

Natera reported a strong second quarter with a 64.2% increase in total revenue compared to the same period last year. The company processed more tests, achieved higher gross margins, and increased revenue guidance for the year.

Natera reported a record quarter with total revenues of $152.3 million, a 62% increase compared to the first quarter of 2020. The company processed approximately 348,200 tests and increased its revenue forecast for the year by $50 million.

Natera reported a 35.1% increase in total revenues for Q4 2020 compared to Q4 2019, driven primarily by product revenue growth. The company also saw a significant increase in the number of tests processed and reported. However, the loss from operations and net loss also increased during the same period.

Natera's Q3 2020 total revenues increased to $98.1 million compared to $77.9 million in Q3 2019, driven by a 39.5% increase in product revenues. The company processed 262,000 tests, including approximately 249,300 tests accessioned in its laboratory. Net loss was $58.3 million, or ($0.72) per diluted share, compared to a net loss of $23.1 million, or ($0.33) per diluted share, for the same period in 2019.

Natera reported total revenues of $86.5 million for the second quarter of 2020, compared to $74.4 million for the second quarter of 2019. The increase was primarily driven by sales of Panorama and Horizon tests. The company processed 234,100 tests in the second quarter of 2020, including approximately 221,600 tests accessioned in its laboratory.

Natera reported a strong first quarter with record revenues of $94.0 million, a 41% increase compared to the first quarter of 2019. The company also processed 235,500 tests and achieved higher gross margins due to increased volume and average selling price.

Natera reported a 24% increase in total revenues for Q4 2019, driven by sales of Panorama and Horizon tests. The company processed 209,400 tests, with 198,300 accessioned in its laboratory, and recognized revenue on 200,800 tests reported, including 189,700 tests accessioned in its laboratory.